Back to NVSView full pipeline
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer
View Full LandscapeDrug Information
Target Indication
Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer
Clinical Trial
NCT07468071Last updated: 9/11/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
zoledronic acid (aclasta)Phase 3
Avascular Necrosis of Femoral Head
acid mycophenolic (Myfortic)Phase 3
Nephrotic Syndrome
anthracycline ((daunorubicin or idarubicin): Induction Phase onlyPhase 3
Acute Myeloid Leukemia
Fluticasone/salmeterolPhase 3
Chronic Obstructive Pulmonary Disease
Aflibercept 2 mgPhase 3
Neovascular Age-related Macular Degeneration
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts